2024年12月期第1四半期決算説明会

This document is a report on the first quarter financial results for the fiscal year ending December 2024, presented by Masuka, the Chairman and Group CEO, and Takada, the President and Domestic CEO. It discusses the comparison with the previous year's first quarter, addressing the impacts of COVID-19 and issues in the pharmaceutical industry, highlighting a decrease in revenue but an increase in operating profit. The document also covers the status of the U.S. subsidiary Xyvid, as well as the progress in the Event DX, Third Place, and Enterprise DX segments. Notably, the achievements in cost reduction and structural reforms are emphasized, indicating expectations for future growth.